Pleural mesothelioma classification-update and challenges.
Dacic S.
Mod Pathol. 2022 Jan;35(Suppl 1):51-56. doi: 10.1038/s41379-021-00895-7. Epub 2021 Aug 31.
Perspectives on the Treatment of Malignant Pleural Mesothelioma.
Janes SM, Alrifai D, Fennell DA.
N Engl J Med. 2021 Sep 23;385(13):1207-1218. doi: 10.1056/NEJMra1912719.
Malignant pleural mesothelioma: recent developments.
Sinn K, Mosleh B, Hoda MA.
Curr Opin Oncol. 2021 Jan;33(1):80-86. doi: 10.1097/CCO.0000000000000697.
New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options.
Tsao AS, Pass HI, Rimner A, Mansfield AS.
J Clin Oncol. 2022 Feb 20;40(6):681-692. doi: 10.1200/JCO.21.01567. Epub 2022 Jan 5.
The Molecular Basis of Malignant Pleural Mesothelioma.
Wadowski B, De Rienzo A, Bueno R.
Thorac Surg Clin. 2020 Nov;30(4):383-393. doi: 10.1016/j.thorsurg.2020.08.005. Epub 2020 Sep 12.
Pleural mesothelioma classification update.
Beasley MB, Galateau-Salle F, Dacic S.
Virchows Arch. 2021 Jan;478(1):59-72. doi: 10.1007/s00428-021-03031-7. Epub 2021 Jan 21.
Asbestos-associated pulmonary disease.
Caceres JD, Venkata AN.
Curr Opin Pulm Med. 2023 Mar 1;29(2):76-82. doi: 10.1097/MCP.0000000000000939. Epub 2023 Jan 11.
Chinese expert consensus on the diagnosis and treatment of malignant pleural mesothelioma.
Wang Q, Xu C, Wang W, Zhang Y, Li Z, Song Z, Wang J, Yu J, Liu J, Zhang S, Cai X, Li W, Zhan P, Liu H, Lv T, Miao L, Min L, Li J, Liu B, Yuan J, Jiang Z, Lin G, Chen X, Pu X, Rao C, Lv D, Yu Z, Li X, Tang C, Zhou C, Zhang J, Guo H, Chu Q, Meng R, Liu X, Wu J, Hu X, Zhou J, Zhu Z, Chen X, Pan W, Pang F, Zhang W, Jian Q, Wang K, Wang L, Zhu Y, Yang G, Lin X, Cai J, Feng H, Wang L, Du Y, Yao W, Shi X, Niu X, Yuan D, Yao Y, Huang J, Wang X, Zhang Y, Sun P, Wang H, Ye M, Wang D, Wang Z, Hao Y, Wang Z, Wan B, Lv D, Yu J, Kang J, Zhang J, Zhang C, Wu L, Shi L, Ye L, Wang G, Wang Y, Gao F, Huang J, Wang G, Wei J, Huang L, Li B, Zhang Z, Li Z, Liu Y, Li Y, Liu Z, Yang N, Wu L, Wang Q, Huang W, Hong Z, Wang G, Qu F, Fang M, Fang Y, Zhu X, Du K, Ji J, Shen Y, Chen J, Zhang Y, Ma S, Lu Y, Song Y, Liu A, Zhong W, Fang W.
Thorac Cancer. 2023 Sep;14(26):2715-2731. doi: 10.1111/1759-7714.15022. Epub 2023 Jul 17.
Multiomic analysis of malignant pleural mesothelioma identifies molecular axes and specialized tumor profiles driving intertumor heterogeneity.
Mangiante L, Alcala N, Sexton-Oates A, Di Genova A, Gonzalez-Perez A, Khandekar A, Bergstrom EN, Kim J, Liu X, Blazquez-Encinas R, Giacobi C, Le Stang N, Boyault S, Cuenin C, Tabone-Eglinger S, Damiola F, Voegele C, Ardin M, Michallet MC, Soudade L, Delhomme TM, Poret A, Brevet M, Copin MC, Giusiano-Courcambeck S, Damotte D, Girard C, Hofman V, Hofman P, Mouroux J, Cohen C, Lacomme S, Mazieres J, de Montpreville VT, Perrin C, Planchard G, Rousseau N, Rouquette I, Sagan C, Scherpereel A, Thivolet F, Vignaud JM, Jean D, Ilg AGS, Olaso R, Meyer V, Boland-Auge A, Deleuze JF, Altmuller J, Nuernberg P, Ibáñez-Costa A, Castaño JP, Lantuejoul S, Ghantous A, Maussion C, Courtiol P, Hernandez-Vargas H, Caux C, Girard N, Lopez-Bigas N, Alexandrov LB, Galateau-Salle F, Foll M, Fernandez-Cuesta L.
Nat Genet. 2023 Apr;55(4):607-618. doi: 10.1038/s41588-023-01321-1. Epub 2023 Mar 16.
Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial.
Pinto C, Zucali PA, Pagano M, Grosso F, Pasello G, Garassino MC, Tiseo M, Soto Parra H, Grossi F, Cappuzzo F, de Marinis F, Pedrazzoli P, Bonomi M, Gianoncelli L, Perrino M, Santoro A, Zanelli F, Bonelli C, Maconi A, Frega S, Gervasi E, Boni L, Ceresoli GL.
Lancet Oncol. 2021 Oct;22(10):1438-1447. doi: 10.1016/S1470-2045(21)00404-6. Epub 2021 Sep 6.
